Skip to content
10-Q

Quarterly Report

POINT BIOPHARMA GLOBAL INC.

0001811764-22-000064

← back to feed
Filed
Aug 12, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2022 · Aug 8, 2022 90.12M sh
Short Term Investments Q2 2022 · Jun 30, 2022 $121.32M
Short Term Investments Q2 2022 · Dec 31, 2021 $0
Cash And Equivalents Q2 2022 · Jun 30, 2022 $78.11M
Cash And Equivalents Q2 2022 · Dec 31, 2021 $238.82M
Current Liabilities Q2 2022 · Jun 30, 2022 $18.8M
Current Liabilities Q2 2022 · Dec 31, 2021 $7.98M
Total Liabilities Q2 2022 · Jun 30, 2022 $18.86M
Total Liabilities Q2 2022 · Dec 31, 2021 $8.05M
Current Assets Q2 2022 · Jun 30, 2022 $204.91M
Current Assets Q2 2022 · Dec 31, 2021 $243.85M
Total Assets Q2 2022 · Jun 30, 2022 $234.24M
Total Assets Q2 2022 · Dec 31, 2021 $263.26M
Shares Diluted Q2 2022 · Jun 30, 2021 57.58M sh
Shares Diluted Q2 2022 · Jun 30, 2021 57.12M sh
Dividends Paid Q2 2022 · Jun 30, 2021 $0
Capex restated Q2 2022 · Jun 30, 2021 $3.24M
Operating Cash Flow restated Q2 2022 · Jun 30, 2021 −$19.44M
Eps Diluted Q2 2022 · Jun 30, 2021 −$0.15
Eps Diluted Q2 2022 · Jun 30, 2021 −$0.26
Eps Basic Q2 2022 · Jun 30, 2021 −$0.15
Eps Basic Q2 2022 · Jun 30, 2021 −$0.26
Sga Expense Q2 2022 · Jun 30, 2021 $1.95M
Sga Expense Q2 2022 · Jun 30, 2021 $3.41M
Rd Expense Q2 2022 · Jun 30, 2021 $6.7M
Rd Expense Q2 2022 · Jun 30, 2021 $10.97M
Net Income Q2 2022 · Jun 30, 2021 −$8.8M
Net Income Q2 2022 · Jun 30, 2021 −$14.59M
Net Income Q2 2022 · Mar 31, 2021 −$5.78M
Operating Income Q2 2022 · Jun 30, 2021 −$8.65M
Operating Income Q2 2022 · Jun 30, 2021 −$14.38M